In this article
In November 2022, Colorado voters passed Proposition 122 — the Natural Medicine Health Act — making Colorado the second state (after Oregon) to create a regulated pathway for psilocybin-assisted therapy. The Act also decriminalized personal use and possession of several naturally occurring psychedelics, including psilocybin, DMT, ibogaine, and mescaline (excluding peyote).
Since then, the regulatory framework has been taking shape. Licensing has begun, facilitation centers are opening, and the conversation has shifted from “should this be legal?” to “how does this actually work in practice?”
This post is an update on where things stand — what’s available, what the clinical evidence supports, who’s a reasonable candidate, and what a responsible mental health practice should be telling you about it.
Where Colorado Stands Right Now
The Department of Regulatory Agencies (DORA) has been building out the licensing and regulatory infrastructure since the Act passed. Here’s the practical picture:
Facilitation centers are beginning to operate. Licensed facilities where adults 21+ can undergo psilocybin sessions with a trained facilitator are opening in stages. These are not therapy offices in the traditional sense — they’re specifically licensed spaces with specific safety and staffing requirements.
Facilitators are not therapists (unless they also are). The facilitator credential created by the Natural Medicine Act is its own license. Some facilitators are also licensed therapists; many are not. This distinction matters — facilitators are trained to support someone through a psilocybin experience, but facilitation alone is not psychotherapy.
Integration therapy is where licensed therapists fit in. Before and after a psilocybin session, the therapeutic work of making sense of the experience — and connecting it to your actual life — is integration. This is where licensed mental health professionals (therapists, psychologists, social workers) have a clear role, and where evidence-based therapy skills matter most.
Insurance does not cover psilocybin sessions. Facilitation center sessions are out-of-pocket. Integration therapy with a licensed therapist may be covered depending on your insurance and how it’s billed (as therapy, not as psilocybin-related care specifically).
What the Clinical Evidence Actually Says
The research on psilocybin-assisted therapy is genuinely promising — and genuinely early. Here’s an honest summary.
Treatment-resistant depression. This is the strongest evidence base. Multiple randomized controlled trials, including landmark studies from Johns Hopkins, NYU, and Imperial College London, have shown significant and sometimes rapid reduction in depression symptoms after one to two psilocybin sessions combined with psychotherapy. The FDA has granted psilocybin “breakthrough therapy” designation for treatment-resistant depression.
End-of-life anxiety and depression. Strong evidence from NYU and Johns Hopkins showing that a single psilocybin session, in the context of psychotherapy, can produce lasting reductions in anxiety and depression in patients with terminal cancer diagnoses. Effect sizes are large and durable (months to years in follow-up).
Alcohol use disorder. A 2022 JAMA Psychiatry trial showed psilocybin-assisted therapy significantly reduced heavy drinking days compared to active placebo. Promising but still early-stage.
PTSD, OCD, eating disorders. Active research is underway. Preliminary results are encouraging but not yet at the level of evidence that supports clinical recommendation. We don’t know enough to say “this works for PTSD” with the same confidence we can say it for depression.
What the evidence does not support: psilocybin as a standalone treatment without therapeutic support. The studies showing strong results all pair psilocybin with structured psychotherapy — preparation sessions before, the guided experience itself, and integration sessions after. The drug alone is not the treatment; the drug-plus-therapy combination is.
Who Might Be a Reasonable Candidate
Based on the current evidence and the clinical consensus forming around best practices:
Potentially good candidates include adults with treatment-resistant depression (multiple medication trials without adequate response), depression or anxiety related to a serious medical diagnosis, and alcohol use disorder that hasn’t responded well to standard treatments.
People who should be cautious or avoid psilocybin include anyone with a personal or family history of psychotic disorders (schizophrenia, schizoaffective disorder, bipolar I with psychotic features), people currently in acute psychiatric crisis, people taking lithium (dangerous interaction), and people taking SSRIs or SNRIs (may reduce psilocybin’s effects — tapering should only be done under medical supervision).
People who need honest guidance include anyone considering psilocybin as a substitute for evidence-based treatment they haven’t tried yet. If you have depression and haven’t done a course of CBT, or you have PTSD and haven’t tried PE or CPT, or you have BPD and haven’t done DBT — the evidence base for those treatments is much stronger and much more established than the evidence for psilocybin. Psilocybin therapy is promising for cases where standard treatments haven’t worked. It’s not a first-line treatment.
What to Watch For — Red Flags in the Psilocybin Space
The rapid growth of legal psilocybin in Colorado has created a landscape where quality varies enormously. Some things to be cautious about:
Facilitators making clinical claims beyond the evidence. “Psilocybin cures PTSD” or “one session can replace years of therapy” — these overstate what the research shows. The evidence is promising, not conclusive, and it’s for specific conditions, not everything.
No screening for contraindications. Any responsible facilitation center should screen for psychotic disorder history, bipolar disorder, current medications, and acute psychiatric conditions before a session. If they don’t ask, that’s a problem.
No integration support. A psilocybin experience without preparation and integration is not therapy — it’s a drug experience. The therapeutic value comes from the work around the session, not just the session itself.
Spiritual or wellness framing that replaces clinical framing. Psilocybin experiences can be profound and personally meaningful. But when a facilitator frames the work as purely spiritual or “healing” without acknowledging the clinical dimensions — screening, contraindications, the limits of the evidence — that’s a flag.
Underground or unregulated sessions marketed as equivalent to licensed facilitation. Colorado’s licensing framework exists for safety reasons. Decriminalization of personal use doesn’t make unregulated facilitation equivalent to licensed practice.
How This Intersects With Traditional Therapy
For most people reading this, the honest answer is: psilocybin-assisted therapy is not yet the right first step, but it may become a valuable option in specific circumstances.
If you’re currently in therapy — whether for depression, anxiety, trauma, or BPD — psilocybin is not a replacement for that work. It’s a potential addition, in specific cases, under specific conditions.
If you’re considering psilocybin because traditional therapy hasn’t helped, two questions worth asking first:
-
Was the therapy evidence-based? Not all therapy is equally effective. CBT for depression, DBT for BPD, prolonged exposure for PTSD — these have robust evidence. “I tried therapy and it didn’t work” sometimes means “I tried a non-evidence-based approach that wasn’t a good match for my condition.” It’s worth making sure you’ve had a genuine trial of the right treatment before concluding that standard approaches have failed.
-
Was the dose adequate? For therapy: did you attend consistently for the recommended duration? For medication: were you at therapeutic doses long enough? Partial treatment courses that end early are common and don’t constitute a fair trial.
FRTC’s Position
We are not a psilocybin facilitation center. We don’t offer psilocybin-assisted therapy and don’t have current plans to.
What we do offer: evidence-based therapy for the conditions where our training is deepest — DBT for BPD and emotion dysregulation, CBT for anxiety and depression, trauma-focused treatment, and couples therapy. These are treatments with decades of evidence behind them.
If you’re considering psilocybin-assisted therapy and want to talk through whether it makes sense given your situation, we’re happy to have that conversation honestly. If integration therapy before or after a facilitated session would be useful, that’s within our scope. And if standard evidence-based treatment is the right move — whether or not psilocybin is also in the picture — we can help with that directly.
The Bottom Line
Colorado’s Natural Medicine Act is a significant policy development, and the clinical research behind psilocybin is legitimately promising for specific conditions. The responsible take is neither hype nor dismissal — it’s honest assessment of where the evidence is strong, where it’s still emerging, and where established treatments remain the better-supported option.
If you’re navigating this landscape and want a therapist’s honest read on what fits your situation, that’s a conversation worth having.
Related Reading
Condition-specific care at FRTC
FRTC programs related to this article.
Need Support?
Our team specializes in evidence-based DBT and CBT therapy. Reach out for a free consultation.